Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.

@article{Park2006EfficacyAS,
  title={Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.},
  author={Jeong Mi Park and Kathleen D. Lake and Juan Sebastian Diosa Arenas and Robert J Fontana},
  journal={Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society},
  year={2006},
  volume={12 1},
  pages={
          112-6
        }
}
The efficacy and safety of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in liver transplant recipients has not been established. We retrospectively compared the efficacy and safety of low-dose oral VGCV (450 mg once daily for 90 days) and standard oral ganciclovir (1 g three times a day for 90 days, GCV) in preventing CMV disease in 109 adult liver transplant recipients who survived at least 1 month between January 2001 and April 2003 (49 GCV and 60 VGCV). The incidence of CMV… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 16 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 13 REFERENCES

Comparative efficacy and safety of low-dose valganciclovir vs oral ganciclovir for the prevention of cytomegalovirus disease in renal allograft recipients [abstract

  • DK Gelone, D Cibrik, S Vogler, AB Leichtman, KD. Lake
  • Am J Transplant
  • 2003
3 Excerpts

Similar Papers

Loading similar papers…